Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Operating Income: 2020-2025

Historic Operating Income for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to -$35.3 million.

  • Janux Therapeutics' Operating Income rose 1.65% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.3 million, marking a year-over-year decrease of 67.85%. This contributed to the annual value of -$98.8 million for FY2024, which is 35.45% down from last year.
  • Per Janux Therapeutics' latest filing, its Operating Income stood at -$35.3 million for Q3 2025, which was up 21.87% from -$45.1 million recorded in Q2 2025.
  • Janux Therapeutics' Operating Income's 5-year high stood at -$2.3 million during Q1 2021, with a 5-year trough of -$45.1 million in Q2 2025.
  • Its 3-year average for Operating Income is -$26.1 million, with a median of -$20.7 million in 2023.
  • Per our database at Business Quant, Janux Therapeutics' Operating Income crashed by 768.07% in 2021 and then soared by 33.38% in 2024.
  • Janux Therapeutics' Operating Income (Quarterly) stood at -$13.5 million in 2021, then tumbled by 35.40% to -$18.3 million in 2022, then increased by 11.66% to -$16.1 million in 2023, then crashed by 79.85% to -$29.0 million in 2024, then climbed by 1.65% to -$35.3 million in 2025.
  • Its last three reported values are -$35.3 million in Q3 2025, -$45.1 million for Q2 2025, and -$34.9 million during Q1 2025.